Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster- Help Your Insusceptibility: Good dieting and Way of life Tips
- Canada's Serene Lakeside Mountain Village Is A Breathtaking Oasis For Outdoor Adventure
- Instructions to Figure out the Various Phases of Cellular breakdown in the lungs
- Step by step instructions to Protect Your Retirement with Senior Protection.
- Instructions to Warmly greet Certainty and Appeal
- The most effective method to Comprehend the Variables Affecting Medical attendant Pay rates
- Man threatens attack on German high-speed train, injures several
- Astounding Treehouses All over the Planet
